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Abstract
On May 3, 2008, a National Cancer Institute (NCI)–sponsored open consensus conference was held in Toronto,
Ontario, Canada, during the 2008 International Society for Magnetic Resonance in Medicine Meeting. Approxi-
mately 100 experts and stakeholders summarized the current understanding of diffusion-weighted magnetic res-
onance imaging (DW-MRI) and reached consensus on the use of DW-MRI as a cancer imaging biomarker. DW-MRI
should be tested as an imaging biomarker in the context of well-defined clinical trials, by adding DW-MRI to ex-
isting NCI-sponsored trials, particularly those with tissue sampling or survival indicators. Where possible, DW-MRI
measurements should be compared with histologic indices including cellularity and tissue response. There is a
need for tissue equivalent diffusivity phantoms; meanwhile, simple fluid-filled phantoms should be used. Mono-
exponential assessments of apparent diffusion coefficient values should use two b values (>100 and between 500
and 1000 mm2/sec depending on the application). Free breathing with multiple acquisitions is superior to complex
gating techniques. Baseline patient reproducibility studies should be part of study designs. Both region of interest
and histogram analysis of apparent diffusion coefficient measurements should be obtained. Standards for mea-
surement, analysis, and display are needed. Annotated data from validation studies (along with outcome mea-
sures) should be made publicly available. Magnetic resonance imaging vendors should be engaged in this
process. The NCI should establish a task force of experts (physicists, radiologists, and oncologists) to plan, orga-
nize technical aspects, and conduct pilot trials. The American College of Radiology Imaging Network infrastructure
may be suitable for these purposes. There is an extraordinary opportunity for DW-MRI to evolve into a clinically
valuable imaging tool, potentially important for drug development.
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Introduction
Imaging biomarkers are important tools for the detection and char-
acterization of cancers as well as for monitoring the response to therapy
[1]. With rapid technological developments, new imaging methods ap-
pear rapidly and their utility requires systematic evaluation. Diffusion-
weighted magnetic resonance imaging (DW-MRI) depends on the
microscopic mobility of water. Thismobility, classically called Brownian
motion, is due to thermal agitation and is highly influenced by the cel-
lular environment of water. Thus, findings on DW-MRI could be an
early harbinger of biologic abnormality. For instance, the most estab-
lished clinical indication for DW-MRI is the assessment of cerebral is-
chemia where DW-MRI findings precede all other MR techniques [2].
In oncologic imaging, DW-MRI has been linked to lesion aggres-
siveness and tumor response, although the biophysical basis for this is
incompletely understood. Parameters derived from DW-MRI are ap-
pealing as imaging biomarkers because the acquisition is noninvasive,
does not require any exogenous contrast agents, does not use ionizing
radiation yet is quantitative and can be obtained relatively rapidly, and
is easily incorporated into routine patient evaluations. However, these
desirable features are offset by many challenges that face the validation
of any imaging-based biomarker.
From the outset, it is important to recognize the many pioneering
contributions of Stejskal and Tanner, Le Bihan et al., and Chenevert
et al. from which as come the knowledge that tissue diffusivity mea-
surements are not always random due to tissue organization and
therefore, have components that can be attributed both to the vas-
cular and the extravascular compartments [3–5]. This weighting is
imparted by the experimental conditions used in measurements
(the b values). This document focuses on extravascular diffusion mea-
surements where the measured signal is related to tissue cellularity,
tissue organization and extracellular space tortuosity, and on the in-
tactness of cellular membranes that are intrinsically hydrophobic.
Classically, the low values of diffusion found in most tumors have
been attributed to their increased cellular density; however, this re-
mains a point of contention because diffusivity is influenced by ex-
tracellular fibrosis, the shape and size of the intercellular spaces, and
by other microscopic tissue/tumor organizational characteristics such
as glandular formations (as in well differentiated adenocarcinomas).
There is an extraordinary opportunity for DW-MRI to evolve into a
clinically useful method that is useful for pharmaceutical drug devel-
opment and for predicting therapeutic efficacy. Potentially, DW-MRI
could have clinical utility at all stages of a cancer patient’s journey from
detection to diagnosis, for staging and assessing therapy response, and
finally, for assessing relapse. As a pharmacodynamic indicator, DW-
MRI may have a significant impact on pharmaceutical drug develop-
ment. It should be recognized that pharmaceutical drug development
and clinical therapeutic efficacy assessments are related but are none-
theless different. In pharmaceutical development, the questions revolve
around whether a drug produces a measurable effect, on the magni-
tude of those effects and the potential biologic implications. In clinical
trials, questions revolve around whether changes in individual patients
can be measured reliably and reproducibly and whether they predict
important clinical outcomes related to therapy.
To truly realize its potential, it is imperative for DW-MRI to be-
come robust so as to provide similar information at different insti-
tutions using differing equipment. To date, no accepted standards
in measurement or analysis methods have been established. Indeed,
it is evident that current implementations of imaging protocols and
analysis by different companies vary significantly; even the same
manufacturer can alter its methods with “upgrades.” There is also a
lack of transparency and a divergent nomenclature among the ven-
dors regarding their particular implementation of DW-MRI, which
impedes efforts to standardize the technique. Furthermore, it is
unclear whether whole body or localized analyses are preferred for
clinical use and for drug development. Finally, multiple analytic ap-
proaches to DW-MRI have been proposed and it is not clear which is
the best for any given situation. For instance, it is unclear what the
optimal set of “b values” should be, how parameters should be ad-
justed with the tumor type and site, and whether the data should be
analyzed monoexponentially, biexponentially, or multiexponentially,
all of which will influence apparent diffusion coefficient (ADC) values.
Diffusion-weighted MRI depends mostly on images obtained with
b value >100 sec/mm2 in extracranial tissues. However, it is acknowl-
edged that the usefulness of information depicted by lower b values has
not yet been fully investigated.
Our purpose was to attempt to summarize the current understand-
ing of the pathophysiologic basis for DW-MRI imaging, to describe
widely accepted methods that depict diffusivity in the extravascular-
extracellular space, and to provide recommendations on standards for
measurement, image display, and analysis methods. We have done
this to bring all stakeholders toward a consensus on how to conduct
multi-institutional trials that will assess the efficacy of DW-MRI for
tumor assessments.
Neoplasia Vol. 11, No. 2, 2009 Consensus on Diffusion-Weighted MRI in Cancer Padhani et al. 103
Emerging Challenges for Widespread Implementation of
DW-MRI as a Means of Assessing Cancer
 Rapid evolution of body imaging protocols
 Divergence among and between vendors on data measurements/
analysis and lack of transparency on how measurements are made
 No accepted standards for measurements and analysis
 Multiple data acquisition protocols depending on body part and
usage of data
 Qualitative to quantitative assessments
 Lack of understanding of DW-MRI at a microscopic level
 Multiexponential decay components which affect the calculated
ADC values
 Incomplete validation and documentation of reproducibility
 Divergent nomenclature and symbols
 Lack of multicenter working methodologies, accepted quality as-
surance (QA) standards, and physiologically realistic phantoms
Biophysical Basis
Diffusion measurements reflect the effective displacement of water
molecules allowed to migrate for a given time [6]. Whereas temperature
modulates molecular mobility in pure water (by approximately 2.4%
per degree Celsius), it is rarely considered a significant factor in DW-
MRI intact tissues because other biophysical properties have far greater
influences on tissue water mobility. Signal-to-noise ratio (SNR) and
T2-relaxation rates set practical limits on the diffusion measurement
interval to within 40 to 80 milliseconds on standard clinical systems.
Using pure water at body temperature (37°C) as a reference standard,
the average displacement of water molecules during a 50-millisecond
interval is approximately 30 μm [9]. Because this is comparable to or
greater than the dimensions of cells, there is a high probability that
water molecules will interact with cells and their hydrophobic mem-
branes and macromolecules will impede the motion of water. As
such, the observed or “apparent” diffusion of water within tissues
is typically several-fold less than in pure water. Moreover, diffusion
in biologic systems is affected by water exchange between intracellu-
lar and extracellular compartments and the tortuosity of the extracel-
lular space (which in turn is affected by cell sizes, organization, and
packing density). Thus, although the spatial resolution of DW-MRI
is typically on the order of millimeters, DW-MRI is exquisitely sen-
sitive to changes in diffusion measured on the cellular scale (e.g.,
micrometers). A clear example of the ability of DW-MRI to docu-
ment directional diffusion from which architectural features can be
derived is the anisotropy depicted in highly directional structures (e.g.,
myelinated white matter fiber tracts) [3,7].
Other biophysical processes can potentially increase apparent water
mobility. These include active transport, flow and perfusion, and
macroscopic/bulk movements such as cardiac and respiratory motions.
Flow, perfusion, and motion have detrimental effects on the accuracy
of measurements of tissue water diffusion and its change over time.
Motion correction, cardiac and respiratory gating, and overaveraging
can reduce the magnitude of these effects.
Given these complexities, undisputed consensus on the appropriate
biophysical interpretation of water diffusion measurements of in vivo
systems is difficult to achieve. Indeed, some authors propose a “low-
mobility intracellular space” and a “high-mobility extracellular space,”
which are averaged on clinical DW-MRI. Although the latter model
has intuitive appeal, it is not well supported by empirical observations
[8,9]. Alternative models based on exchange between distinct diffusion
domains that coexist in the same physical compartment offer better fits
of empirical data, although the development and application of these
models require measurements over a broader range of b values and
more diffusion settings than are typically used in clinical settings.
There are a limited number of validation tools available to confirm
that properties, such as water diffusion, compartmental tortuosity,
and interactions with cell membranes, actually influence diffusion
measurements on DW-MRI.
Blood flow signal is rapidly attenuated at low b values (e.g., b <
100-150 sec/mm2) and may be mistakenly attributed to diffusion.
This phenomenon, also known as the intravoxel incoherent motion
(IVIM), has been used to assess tissue perfusion [5]; however, for
clarity in this communication, we exclude blood flow and perfusion
from diffusion phenomena and confine our comments to water mo-
bility in the extravascular space.
Higher minimum b values are required to suppress the perfusion
in vascular-rich tissues, indicating that appropriate minimum b val-
ues may vary across applications depending on intrinsic vascularity.
Even after elimination of perfusion effects, tissues are known to ex-
hibit multiexponential signal decay. Typically, very high b values (b =
1000-5000 sec/mm2) are required to reliably quantify the biexpo-
nential decay constants, “Dfast” and “Dslow” [10,11]. Alternatively,
nonmonoexpential decay behavior may be fit to a stretched exponen-
tial model that yields a distributed diffusion coefficient and an index
representing degree of intravoxel diffusion heterogeneity [12]. There-
fore, the notion of “low” and “high” b values is relative and depen-
dent on the tissue being studied and the SNR available to maximize
diffusion contrast.
Physical Basis
 Diffusion-weighted MRI is sensitive to thermally driven molecu-
lar water motion, which in vivo is impeded by cellular packing,
intracellular elements, membranes, and macromolecules. Thus,
DW-MRI provides insights to cellular architecture at the milli-
meter scale.
 Sensitivity to diffusion-based contrast is primarily controlled
by the b value with the appropriate b-value range dependent
on tissue diffusion properties, SNR, and the need to suppress
perfusion effects effectively at low b values.
 Tissues are known to exhibit multiexponential signal decay
over a broad range of b values, indicating the need for a better
understanding to elucidate the fundamental biophysical prop-
erties of water movement within the cellular matrix.
Clinical View
Diffusion-weighted MRI is already being incorporated into general
oncologic imaging practice because of its many clinical advantages
[13,14]. A particular advantage of DW-MRI is that it does not re-
quire intravenous contrast media, thus enabling its use in patients
with reduced renal function. Its clinical uses include improved tissue
characterization (differentiating benign from malignant lesions), for
monitoring treatment response after chemotherapy or radiation, for
differentiating posttherapeutic changes from residual active tumor,
and for detecting recurrent cancer. Potential additional roles include
predicting treatment outcomes (before and soon after starting therapy),
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for tumor staging, and perhaps also for detecting lymph node involve-
ment by cancer.
Tissue Characterization
The reason(s) why malignant tumors have lower ADC values are
poorly understood but is probably related to a combination of higher
cellularity, tissue disorganization, and increased extracellular space
tortuosity, all contributing to reduced motion of water (Figures 1
and 2). Correlations with cellularity have been found for some pri-
mary and secondary neoplasms [15–20] but not for all tumors such
as adenocarcinomas and necrotic lesions that correlate only weakly
[15,21]. Diffusion-weighted MRI is able to differentiate between be-
nign and malignant focal hepatic lesions in many cases based on the
higher ADC of benign lesions compared with malignant lesions [22].
However, when cystic, necrotic, or treated metastases are included,
results in the liver are not as good [23]. In line with these findings,
reduced ADC values of malignant breast tumors compared with
those of benign lesions and normal tissue have also been noted
[16,24,25]. Sumi et al. [26] showed that lymphomatous nodes
had significantly lower ADC than benign nodes. However, in the
same study, metastatic cervical lymph nodes in patients with head
and neck cancers had significantly higher ADC values than benign
nodes. This apparent discrepant result can be explained by the com-
mon occurrence of necrosis in nodes with metastatic squamous cell
carcinomas [26]. In a confirmatory study, the ADC values of lym-
phomas were reported to be lower than those of squamous cell carci-
nomas [27]. These and other studies indicate that false-positive results
occur with abscess and infective processes and false-negatives occur
with cystic, necrotic lesions and in well-differentiated neoplasms (par-
ticularly adenocarcinomas).
Monitoring Treatment Response
Because cellular death and vascular changes in response to treatment
can both precede changes in lesion size, changes in DW-MRI may be
an effective early biomarker for treatment outcome both for vascular
disruptive drugs and for therapies that induce apoptosis [14,28,29].
Preclinical work has shown that DW-MRI is able to discriminate be-
tween nonperfused but viable and nonperfused, nonviable (necrotic)
tissues, when tumors are treated with the vascular disruptive agent
combrestatin-A4-phosphate [30]. In most malignant tumors, success-
ful treatment is reflected by increases in ADC values. Rising ADC
values with successful therapy have been noted in several anatomic
sites, including breast cancers [31,32], primary and metastatic cancers
to the liver [33,34], primary sarcomas of bone [15,35], and in brain
malignancies [36].
Soon after initiation of therapy, transient decreases in ADC can
also be observed; this seems to be related to cellular swelling, re-
ductions in blood flow, or to extracellular space (the latter maybe
Figure 1. Restricted diffusion within rectal cancer with extension into the perirectal space. T2-weighted image demonstrate a well-
circumscribed lesion in the perirectal space. Diffusion-weighted image obtained at a b value of 750 demonstrates a high signal, and
corresponding ADC map demonstrates relatively restricted diffusion within the tumor.
Figure 2. Restricted diffusion within a prostate cancer. T2-weighted scan demonstrates a well-circumscribed tumor in the left peripheral
zone. The ADC map demonstrates restricted diffusion within the tumor.
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mediated by vascular normalization if antiangiogenic drugs are given).
For instance, it has been noted that anti–vascular endothelial growth
factor therapies in brain tumors lead to an initial reduction in vaso-
genic edema that lowers ADC values [37]. The extent and duration
of such ADC reductions is likely to depend on the type of treatment
administered, tumor type, and the timing of imaging with respect to
the treatment. Cellular swelling has been noted to occur in the early
phases of apoptosis in response to anticancer treatment [14]. Apparent
diffusion coefficient values can be reduced by fibrosis and dehydration
after successful treatment as reported in rectal cancers [35] and in brain
gliomas [37]. These additional observations indicate that ADC
changes are dependent on complex interplays of biophysical processes,
emphasizing the need to better understand at a histologic level, tissue
changes reflected in ADC maps.
Posttherapeutic Changes Versus Recurrent/Residual
Active Tumor
The differentiation of posttreatment changes and residual or recur-
rent tumor is a common diagnostic dilemma. In head and neck tumors,
for instance, recurrent tumor and chondroradionecrosis are often im-
possible to distinguish clinically or by imaging [38]. Diffusion-weighted
MRI has the potential to distinguish postradiation changes from recur-
rent cancer based on ADC value differences. Higher ADC values likely
represent posttherapeutic extracellular edema, whereas lower values
are suspicious for active disease. Simple visual assessments of signal
intensity on high–b value DW images may be helpful for image inter-
pretation, with hyperintensity associated with lower ADC values sug-
gesting active tumor. In this respect, DW-MRI may have advantages
over fluorodeoxyglucose–positron emission tomography (FDG-PET)
assessments, which can be limited shortly after radiation therapy be-
cause areas of inflammation often have high uptake on PET scans
and can lead to false-positive results [29].
Predictive Parameter for Treatment Outcome
Diffusion-weighted MRI has been shown to have the potential
to prospectively predict the success of some treatments in a number
of different tumors [30,33,36,38–43]. For example, strong nega-
tive correlations between pretreatment tumor ADC in patients with
rectal cancer and size changes after chemotherapy and chemoradia-
tion have been found [40]. This and other similar observations have
led to the hypothesis that tumors with higher ADC levels are more
likely to have areas of necrosis, which in turn predicts poor outcomes
related to hypoxia-mediated radioresistance. This relationship be-
tween poor outcomes and high pretherapy ADC may not apply to
all tumors and to all therapy types. For example, in an animal tumor
model treated with a vascular disruptive agent, low tumor ADC val-
ues still had viable tumor cells on histologic diagnosis after therapy,
whereas tumors with higher ADC values had a greater degree of cell
kill [39].
Tumor Staging
There is early experience indicating that DW-MRI may be helpful
for primary tumor staging [44] and for detecting nodal [26,27] and
distant metastases [45]. In this regard, whole-body DW-MRI seems
to be particularly promising [46]. Determining threshold ADC val-
ues and confounding effects that can allow/impede the differentia-
tion of benign and malignant lymph nodes will be important goals
for future clinical studies.
Clinical View
 In general, tumors have lower ADC values, whereas normal/
benign/reactive tissues have correspondingly higher values.
 Apparent diffusion coefficient values for distinguishing ma-
lignancy from normal/reactive tissues and benign disease are
dependent on histologic characteristics such as tumor type, dif-
ferentiation, and necrosis.
 Threshold ADC values for the different tumor types and or-
gans need to be defined taking into account data acquisition
parameters.
 Diffusion-weighted MRI may be an effective early biomarker
for treatment outcome for both antivascular drugs and therapies
that induce tumor cell apoptosis. It is unclear how effective
DW-MRI will be for monitoring the effects of other classes
of anticancer therapies.
 Diffusion-weighted MRI protocols and analysis methods need be
tailored to individual tumor types, anatomic sites, and therapies.
 Successful treatment is generally reflected by an increase in
ADC values; however, transient early decreases in ADC values
can be seen after treatment.
 Complex interplays of biophysical processes are reflected in
changes in ADC, underlining the need to define more clearly
the acquisition and analytic protocols.
 The prognostic significance of pretreatment ADC values stems
from the relationship between necrosis and poorer patient
outcomes.
Neuroradiologic Perspective
Diffusion-weighted MRI has a number of roles in neuroradiology
including the diagnosis of acute stroke as early as 30 minutes after the
onset of ischemia [47], compared with the hours-to-days range for
computed tomography and other MRI sequences. For this reason,
DW-MRI has easily and quickly surpassed all other imaging tech-
niques in the initial evaluation of acute stroke patients. In the acute
stroke setting, DW-MRI can also be used with perfusion imaging
to predict the likely clinical outcome after thrombolytic therapy
and estimate the chances of secondary hemorrhagic transformation
[48,Chalelaet,et,al,2007,83]. Other uses of DW-MRI include differ-
entiating brain abscesses from other abnormalities that may mimic
abscesses, with high sensitivity (96%) and specificity (96%) [49],
with the exception of differentiating toxoplasmosis from lymphoma in
HIV-positive patients [50]. Diffusion-weighted MRI can also be used
for predicting the extent of neuronal damage after status epilepticus
[51], for differentiating arachnoid cysts from intracranial epidermoid
cysts, and for evaluating residual epidermoid tumor after surgical re-
section [52].
In the differential diagnosis of cystic brain lesions, DW-MRI can
help distinguish abscesses from necrotic primary brain tumors such
as high-grade gliomas, with lower ADC values usually detected in
abscesses. Lower water diffusivity in abscesses is probably related to
the presence of microorganisms, macromolecules, and intact inflam-
matory cells [49]. When intracranial masses are solid, the main de-
terminant of diffusivity is the volume of the extracellular space. With
a larger extracellular volume, which may be caused by edema/fluid ac-
cumulation, ADC values are higher, whereas tumor hypercellularity
has the effect of restricting diffusion by decreasing the extracellular
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volume. Lower ADC values in lymphomas, compared with gliomas,
correlate well with measures of cellularity [16] (Figures 3 and 4). Ap-
parent diffusion coefficient values also correlate with tumor cellularity
in astrocytomas [20,53], although the value of DW-MRI in tumor
grading is still debated. Diffusion-weighted MRI has also been inves-
tigated as a biomarker of response to treatment in brain tumors, with
increased diffusion values detected shortly after treatment initiation
suggesting a favorable outcome [42,54,55].
Diffusion tensor imaging (DTI), which provides directionality to
diffusion measurements, can be used to assess the relationships be-
tween tumor and nearby white matter tracts, potentially differentiat-
ing tumor infiltration of white matter tracts from displacement, which
can be useful for preoperative planning [56]. Fractional anisotropy
(FA), the degree to which diffusion is directed in a particular direc-
tion, is generally reduced in primary brain tumors owing to disorga-
nized architecture resulting from neuronal death, axonal loss, and
irregular tumor cellular growth [57]. Fractional anisotropy reductions
also correlate with tumor cellularity and percentage tumor infiltra-
tion [58].
Neuroradiology View
 The main clinical application of DW-MRI in neuroradiology
is in the diagnosis of acute ischemia.
 In the evaluation of brain tumors, DW-MRI reflects tumor
cellularity and it can help differentiate brain abscesses from
necrotic tumors.
 Diffusion tensor imaging can help assess the relationship be-
tween tumor and nearby white matter tracts, potentially dif-
ferentiating tumor infiltration from displacement.
Oncologic Viewpoint
Diffusion-weighted MRI has the potential to assist in new drug de-
velopment and in clinical practice. To be accepted in either area requires
that DW-MRI be validated as an accurate biomarker. This will require
systematically conducted prospective studies where patients are assessed
by both DW-MRI, and standard criteria. Diffusion-weighted MRI will
only be accepted if it is shown to provide accurate information earlier,
Figure 3.Minimally restricted diffusion in brainstem glioma: Axial T2-weighted image (A) at the level of middle-cerebellar peduncles shows
slightly heterogeneous, predominantly hyperintense midline mass without significant surrounding edema. There is associated effacement
of the fourth ventricle. Axial isotropic DW image (B) and ADCmap (C) demonstrate no significant restricted diffusion. Instead, the ADCmap
demonstrates increased signal intensity compared with normal brain parenchyma, reflecting increased diffusion of water.
Figure 4. Restricted diffusion in CNS lymphoma: Axial enhanced T1-weighted image (A) of the brain shows a slightly heterogeneously
enhancing hyperintense left frontal mass with minimal surrounding edema. Axial isotropic DW image (B) and ADC map (C) demonstrate
restricted diffusion, suggestive of increased tumor cellularity.
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quicker or easier than current methods, or can provide information un-
attainable with other modalities.
Potential in Clinical Drug Development
In clinical drug development, it would be important to see if a
drug in a phase 1 study alters ADC and in which direction. It would
be relatively easy to add DW-MRI to studies that were already per-
forming serial MRI studies but it would seem sensible to look at ear-
lier time points. This is because of the need to identify the time point
of maximal response; it is only after defining this point correctly in
phase 1 trials that DW-MRI could be incorporated into phase 2 and
3 studies where the opportunities to perform multiple repeat studies
are limited. Furthermore, serial DW-MRI measurements that include
early time points are essential to avoid false-negative results. Data from
multiple studies with a wide variety of different agents incorporating
DW-MRI would have to be available, before “go–no-go” decisions
were made based on whether changes in ADC were seen.
If changes in ADC were seen in the phase 1 or early phase 2 studies
of a new drug, it would be useful to incorporate DW-MRI measure-
ments into phase 3 trials. Changes in ADC would then be correlated
with Response Evaluation Criteria in Solid Tumors (RECIST)–defined
responses, progression-free survival, and survival. If there were robust
correlations between changes in ADC and one of the other efficacy
end points, one could examine whether DW-MRI added value to the
trial. One added value would be an earlier prediction of drug activity
than is possible with other biomarkers. Another would be a better pre-
diction of response than by standard criteria.
Care should be exercised in comparing responses according to
RECIST and responses according to DW-MRI. For general use, it
would be necessary to produce internationally accepted definitions
for response/nonresponse on DW-MRI (these are not currently avail-
able). To produce such definitions requires analyzing numerous trials
where DW-MRI results and standard end points are available. Cor-
relation with survival or progression-free survival is far more impor-
tant than correlation with RECIST response, which is just another
surrogate marker of activity. If DW-MRI does predict response, it
might indicate responses in some patients where RECIST does not
and vice versa. If, for instance, a rise in ADC is associated with apop-
tosis, this effect might be associated with stable disease rather than
partial response, yet such a drug might be valuable in extending sur-
vival. In such a situation, RECIST might indicate that a drug was
inactive, but higher ADCs might be an early indicator that the drug
is effective as maintenance therapy.
To validate DW-MRI as a biomarker, similar methods could be used
as were used to validate the serum tumor marker CA-125. For example,
rather than trying to correlate DW-MRI with RECIST response in in-
dividual patients, one could determine whether DW-MRI was able to
classify the drug as active or not. Such an approach is particularly useful
when different patients might be classified as responders by different
techniques [59].
Another area that DW-MRI could have value in clinical trials is
if it could predict which patients are most likely to benefit/not bene-
fit from a drug/approach. Enriching a population to increase the pro-
portion of patients benefiting is becoming increasingly important as
drug development costs rise. It might, however, be difficult to deter-
mine an absolute ADC value that has predictive power (given the
complexities of data acquisition and analysis methods particularly
when examinations are done on different scanners).
Potential of DW-MRI in Individual Patient Management
A technique that can detect drug efficacy at an earlier time point
has great potential in clinical oncology practice where there is a desire
to stop ineffective therapy as quickly as possible especially if that ther-
apy has severe adverse effects and is very expensive or where there are
alternative approaches to treatment available. However, to change ther-
apy based on a new technique requires having confidence about its
accuracy. Large studies would be required to determine the sensitivity
and specificity of DW-MRI for predicting activity in groups of pa-
tients. However, to change therapy on individuals also requires knowl-
edge of measurement error. Depending on the alternative strategy to
be used, a very high individual value in the positive predictive value/
negative predictive value (PPV/NPV) would be required. Furthermore,
it would be necessary to demonstrate that DW-MRI was able to pro-
vide information that was more accurate or was not available by other
techniques and that it was widely available at a realistic cost. This as-
pect of DW-MRI development is illustrated in Appendix 2.
One could envisage that DW-MRI could give information about
a tumor that would provide both prognostic and predictive infor-
mation. The use of imitanib for gastrointestinal stromal tumors and
trastuzumab for HER2-positive breast cancers are examples of the
few situations where the activity of the new molecular targeted agents
can be predicted by pretreatment investigations. There are no tests that
predict which patients are most likely to benefit from new antiangio-
genic, vascular disruptive agents, or other novel proapoptotic drugs.
Only well-designed prospective studies will demonstrate whether
DW-MRI can help predict which patients are most likely to benefit
from such agents. Such studies might ultimately show that an absolute
pretreatment ADC value below a specified range or an absence of
change in serial ADC values once treatment has started is associated
with a worse prognosis. However, the availability of yet another prog-
nostic marker is unlikely to be widely used (given the higher cost of
imaging tests compared with serology, for example) unless such infor-
mation leads to changes in therapy.
Pharmaceutical Industry View on the Potential
Role of DW-MRI in Drug Development
Many new therapeutics are presently entering development as a
result of increased understanding of the molecular and genetic path-
ways controlling cellular function. Many of the structural and func-
tional components of the cancer/host cell surface, cytoplasm, and
nucleus are being explored for their potential value as therapeutic
targets. Targeted molecular approaches typically seek to inhibit the
cellular processes characteristic of the cancer phenotype. These new
drugs may have complex and possibly even contradictory effects on
water diffusion.
Central to the success of this process are the go–no-go decisions
made in early clinical trials, an important aim of which is to reduce
the high cost of pivotal (phase 3) trials. Because no single biomarker
or assay is used to make such judgments, imaging will need to estab-
lish its place before being integrated into decision-making processes.
Strategic responses of the pharmaceutical industry to overcome
current bottlenecks that result in delays to delivery of new drugs
to market include using novel clinical trial designs and investments
in novel technologies. Clinical trials are now being designed with the
expectation of real-time data analysis and delivery. Imaging, together
with other biomarkers, is recognized as providing accurate and repro-
ducible data capable of enhancing decision making at critical mile-
stones in the drug development process.
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With this in mind, the important end points for imagers to con-
sider include
 Early assessment of response
 Prognosis
 Survival estimate
 Recommendation of an optimal biologic dose
 Identification of the mechanism of drug action
Translational and early clinical development is well suited as a
focus for DW-MRI in drug development. The nonionizing nature
of DW-MRI and avoidance of contrast agents are conducive to serial
patient examinations in exploratory early-phase drug trials. By their
nature, early-phase clinical trials would allow the timely inclusion of
preclinical DW-MRI information to select clinical imaging schedules
and assess the likely clinical sensitivity and specificity of the tech-
nique. Key questions in early clinical trials include Has there been
a change caused by the drug detectable by DW-MRI? What is the
confidence that such a change has occurred? What is the magni-
tude of the change? What is the meaning or predictive value of the
changes observed?
The limited sample size in early-phase clinical trials provides the
opportunity for the rapid accumulation and interpretation of imag-
ing data across many tumor types and therapeutics. Although this
approach needs to be balanced against the limits of small sample size,
studies should have a clearly stated aim(s) focused on one or more of
the end points given above.
There is no reason to think that DW-MRI will be preferred for
any specific class of drug. Any therapeutic could be investigated by
DW-MRI, and the mechanism of action of a drug should not ex-
clude consideration of this technique as long as the biology and sen-
sitivity of the technique support its rational use. As a starting point,
the drug mechanism(s) most likely to be detected by DW-MRI are
those likely to alter the microenvironmental architecture (i.e., apop-
tosis and angiolysis). The preclinical and evolving clinical experience
of DW-MRI in clinical trials suggest its use as a pharmacodynamic
biomarker (the manner in which the drug affects its intended target).
Such data might provide insight into (1) dose scheduling in single or
combination therapy and optimal drug formulation (e.g., oral vs intra-
venous administration).
Because DW-MRI has the potential to provide unique information
for decision making, procedural rigor will be needed to establish it as a
biomarker. Technical reproducibility needs to be determined to define
significant thresholds of change in diffusion indices. Great emphasis
needs to be placed on the need for reproducible examinations suited
for the multicenter and global structure of early-phase clinical trials. In
addition, there needs to be a rational basis for the choice of scanning
times given the mechanism of the drug being assessed. Acquisition se-
quences, data transfer, and analyses all need to be standardized to allow
future meta-analyses and comparisons of results.
Pharmaceutical Perspectives
 Diffusion-weighted MRI is one of several technology-based
tools that could support decision making in the drug develop-
ment process, the aim being to increase the likelihood of suc-
cess in later more costly trials.
(continued )
 Information from DW-MRI has to be placed in the context of
other information from the clinical trial and the relative value
of DW-MRI data compared with other biomarkers needs to
be established. Diffusion-weighted MRI can be used for more
than simply making go–no-go decisions. If DW-MRI was
found to be providing information about patient outcome
then its value could be increased.
 As the pharmaceutical industry moves toward complex multi-
targeted therapies, the anticipated effects on ADC measure-
ments become more difficult to predict. It is likely that the
imaging protocols and analyses will need to be highly custom-
ized to the individual drugs/combinations.
 Improved information is needed about the sensitivity, specific-
ity, biologic meaning, and predictive value of DW-MRI be-
fore it will be routinely implemented in drug development
environment. Such information may be gained from appro-
priate patient stratifications in well-conducted clinical trials,
using standardized protocol acquisitions, central data collec-
tions, and analyses and assessments of intrapatient, intersite,
and intermanufacturer scanner reproducibility.
Role of DW-MRI: A View from The Imaging
Systems Industry
Diffusion-weighted MRI clearly differentiates itself from other imag-
ing modalities both within the MRI “space” and outside as the only
imaging modality able to depict water movement at a cellular level. Eva-
luations of the value of DW-MRI as a “contrast mechanism” leading to
new clinical applications could open up new market segments encour-
aging more sales for MRI equipment and innovations in this area. If
DW-MRI can be shown to be a robust and reproducible early biomarker
of response to anticancer therapies, which is useful for drug development
or for making patient decisions, then this would allow the installed MRI
market to increase further. Improved understanding of the mechanisms
that determine tissue diffusivity and ADC changes in response to ther-
apy would encourage more rapid dissemination of the method.
To enable such developments to occur, it is absolutely necessary
that there are agreements among all stakeholders on standards for
both acquisition protocols, repeatability/reproducibility and for the
postprocessing procedures, to ensure that quantitative ADC values
have similar meanings across vendors and institutions. The setting
down of such standards in cooperation of the scientific imaging com-
munity will allow vendors to focus their research and development
resources on improving measurement and analysis methods.
Imaging System Industry View
 Diffusion weighting is unique to nuclear magnetic resonance and
helps MRI to differentiate itself from other imaging modalities.
 Because the technique is quantifiable and can be repeated easily,
new applications have the potential to open new market seg-
ments especially to the pharmaceutical sector but also for clini-
cal trials and screening.
 Standardization will allow the vendors to focus their research
and development resources on improving measurement and
analysis methods, repeatability, and reproducibility.
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Recommendations for Phase 1/2 Trials of
Anticancer Therapeutics
Diffusion-Weighted MRI Measurements
Recognizing that there are several DW-MRI data acquisition tech-
niques, the most commonly implemented basis sequence is the sin-
gle and double spin-echo Stejskal-Tanner echo planar image (EPI)
experiment [60]. The following comments apply to clinical imag-
ing at 1.5 and 3.0 T but may vary and need adjustment according
to field strength. To ensure high quality images for both qualitative
and quantitative assessments, scanning factors should be optimized
to maximize SNR and reduce artifacts (e.g., from motion, incomplete
fat suppression, residual eddy currents induced by diffusion gradients,
and EPI-related artifacts). In the body, DW-MRI can be performed
using breath-hold, free breathing, or respiratory/cardiac–triggered
techniques as dictated by specific anatomic locations [61]. Scanning
parameters should be prescribed to allow accurate and reproducible
ADC quantification, and the chosen parameters should ideally be
achievable across MR platforms to allow meaningful comparison of
results. The scanning parameters should be clearly stated in reports
and manuscripts.
Ensuring high-quality DW-MR images. The following summa-
rizes the key factors that would help to optimize image quality [61].
Optimizing SNR
1. Parallel imaging should be used in the body as this shortens
echo-train lengths and reduces susceptibility and magnetic field
inhomogeneity-related artifacts.
2. Multiple averaging commensurate with field strength should be
used. The ability to acquire additional averages at higher b value
(e.g., >500 sec/mm2) can be advantageous to compensate for re-
ductions in SNRs at high b values.
3. The echo time (TE) should be held as short as achievable (typ-
ically 50-90 milliseconds at 1.5 T and even shorter at 3 T).
4. Tetrahedral encoding or other simultaneous application of gradient
schemes (e.g., three-scan trace (Siemens), gradient overplus (Phi-
lips)) should be used to achieve the shortest possible TE, which also
reduces the effect of eddy current–induced image distortions.
Reducing artifacts
The following imaging techniques can help reduce motion artifacts
1. Parallel imaging in the body reduces the time of acquisition and
phase encoding and it should be used wherever possible.
2. The shortest TE achievable should be used.
3. Multiple averaging or breath-hold single shot techniques.
4. Respiratory triggering [62] and/or cardiac gating when imaging
the chest and upper abdomen.
5. Antiperistaltic agents for examinations of the lower abdomen
and pelvis.
Fat suppression
1. Optimized fat suppression techniques should always be used in the
body to reduce ghosting artifacts. When performing DW-MRI
over large FOVs on a 1.5-T system, short-tau inversion recovery
(STIR) may be more useful than other methods in achieving uni-
form fat suppression.
2. For examinations targeted to specific organs or anatomic regions,
spectral spatial fat saturation (e.g., spectral presaturation attenu-
ated by inversion recovery (SPAIR), Chemical Shift Selective),
can be advantageous [45]. Considerations should also be given
to using water excitation as a method for fat suppression.
3. Owing to B1 field inhomogeneities at 3 T, optimal fat suppres-
sion is more challenging, and frequency-selective spectral fat sat-
uration may be more successful.
4. Where available, use advanced or higher-order shimming techniques.
Eddy currents and EPI-related artifacts
1. Eddy currents related to diffusion gradients and EPI techniques
lead to geometric distortions and image shearing, which can be
reduced by increasing readout bandwidths or reducing the echo
spacing, conversely reducing the length of image readout. For
body imaging, this is typically 1 to 2 kHz per pixel. However,
increasing bandwidths increases noise and Nyquist ghosting,
and so bandwidths or echo spacing settings should be optimized.
2. Patients who have recently had (within 7 days) superparamag-
netic iron oxide particles as diagnostic agents may not be good
candidates for DW-MRI owing to susceptibility induced by the
presence of the iron oxide in some tissues such as the liver. How-
ever, ultrasmall superparamagnetic iron oxide particles, which
are also taken up in normal lymph nodes, may improve speci-
ficity of DW-MRI by suppressing signal from normal but not
pathologic nodes.
Diffusion-weighted MRI for qualitative assessment. To maximize
tumor visualization and characterization, adequate suppression of
background signals arising from normal tissue is desirable. Diffusion-
weighted MRI should be performed with sufficient degrees of diffusion
weighting (by appropriate choices of b values), with considerations
given for the anatomic region, tissue composition, and pathologic pro-
cesses as indicated in Table 1. This may require the customization of
DW-MRI protocols for different tumor types and tumor locations.
Both native high b value DW-MR images and the ADC maps are
useful for visual assessments of DW-MRI data; both should be eval-
uated with corresponding morphologic images. Cellular tissues gener-
ally demonstrate high signal intensity on high–b value images, but
yield low ADC values. This pattern is occasionally seen in viscous
fluids also such as postoperative cavities and abscess emphasizing the
need to undertake correlative imaging with other morphologic MRI
sequences including those using contrast medium enhancements.
Table 1. b Values That May Be Appropriate for Qualitative Tumor Evaluations.
b Values (sec/mm2) Anatomic Regions
>1000 Brain, prostate, uterus, cervix, lymph nodes
750-1000 Brain, neck, breast, chest, general abdomen (including colorectal,
pancreas, kidneys, peritoneum), lymph nodes, pelvis (including
prostate, uterus,cervix, ovaries, bladder). Also for whole-body
imaging (diffusion-weighted whole-body imaging with background
body signal suppression).
100-750 Liver (primary and metastatic disease)
<100 Used for the detection of liver lesions (“black blood technique”)
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Conversely, cystic or necrotic tissues show greater signal attenuation on
high–b value images and have high ADC values (in this context, the
definition of “necrosis” needs to be established). The latter pattern is
sometimes also seen in well-differentiated neoplasms.
Interestingly, some normal and pathologic tissues exhibit high sig-
nal intensity on high–b value DW-MRI and also return high ADC
values. In these cases, the high signal intensity observed on DW-
MRI cannot be attributed to limitations in water diffusion but result
from the intrinsically long tissue T2-relaxation times; an effect known
as “T2-shine through.” In some anatomic regions (e.g., prostate
gland), ADC maps may be more helpful for disease detection because
T2-shine through from the normal peripheral zone and may mask
disease even on high–b value DW-MR images.
Fibrosis may appear low in signal intensity on DW-MRI and re-
turn low ADC values, but the range of the imaging appearances of
fibrotic tissue has not been fully characterized.
Table 1 summarizes b values that may be used as a guide when
performing DW-MRI for qualitative assessment [18,22,39,63–69]. For
some tissues (e.g., prostate, lymph nodes), b values >1000 sec/mm2 are
occasionally needed to mitigate the effects of “T2-shine through.”
Diffusion-weighted MRI for ADC quantification. Meaningful
comparisons of DW-MRI from different imaging centers with data
acquired from different platforms are more likely to be realized if
DW-MR images are quantified.
Apparent diffusion coefficient quantification obtained using breath-
hold DW-MRI is less reproducible compared with ADC obtained
using free breathing techniques. However, ADC values obtained using
free breathing techniques mask tissue heterogeneity owing to partial
volume averaging effects. The relative balance between these two
trends may vary in different parts of the body thereby necessitating
different approaches.
In the absence of conclusive data demonstrating the superiority of
ADC derived from either breath-hold or free breathing techniques for
assessing treatment response, both techniques should be investigated.
The following should be considered when performing DW-MRI
for ADC quantification:
1. Imaging should cover the entire target lesion.
2. The target lesion should not be chosen in areas prone to suscep-
tibility, ghosting, and other EPI-related artifacts (e.g., base of the
neck, left lobe of the liver, adjacent to the heart, adjacent to me-
tallic surgical sutures/prosthetics/seeds, or across areas with vis-
ible ghosting artifacts). Target lesions can include bony lesions
(sclerotic or lytic).
3. Target lesions should measure at least 2 cm in the mini-
mum diameter.
4. There is controversy about whether partially necrotic lesions
should be excluded from evaluations. This is because some ther-
apies seem to work better in tumors that have higher ADC val-
ues (e.g., vascular targeting agents) [39]. Other treatments (such
as chemotherapy and radiation) seem to work better with more
cellular tumors. These observations underline the need to pro-
spectively define tumor “necrosis” in clinical trials.
5. For ADC quantification in the liver or upper abdomen, con-
sider performing measurements in the fasting state to minimize
air in the stomach, which may degrade images of the left he-
patic lobe.
6. The repetition time (TR) should be sufficiently long to avoid T1-
saturation effects, which result in underestimation of ADC values.
7. The TE should be kept as short as possible as this results in
better SNR and it minimizes motion and susceptibility EPI-
related artifacts.
8. Three or more b values should be used. This should include b =
0 sec/mm2, a b value of ≥100 sec/mm2, and a higher b value
of ≥500 sec/mm2 (typically 500-750 sec/mm2). b values of
>1000 sec/mm2 are less optimal for ADC calculation because of
poorer SNR at very high b values, unless the aim is to evaluate the
exponential behavior of the signal attenuation.
9. The choice of three b values as recommended above should en-
able calculation of perfusion-insensitive ADC values (by exclud-
ing the b = 0 sec/mm2 image from the ADC calculation). The
degree of perfusion bias in ADC measurement increases with
volume fraction of flow and decreases b-value range. For exam-
ple, consider tissue having a true ADC = 1.0 × 10−3 mm2/sec. If
the volume fraction of flow is 0.05 (i.e., 5% of signal from flow-
ing blood), the apparent ADC measured between points b = 0
and 1000 sec/mm2 is overestimated by approximately 5.1%.
If the flow fraction increases to 10%, the measured ADC is in-
flated by 10.5%. Moreover, if the measurement is made between
b = 0 and 500 sec/mm2, the perfusion-induced ADC overesti-
mation increases to 21%. It is therefore recommended to have
low a b value sufficient to extinguish the flow signal (e.g., low
b ≥ 100 sec/mm2) while maintaining adequate diffusion con-
trast between low– and high–b value settings. An obvious draw-
back of this requirement is additional scan time because even
moderately low b values should be acquired along three orthog-
onal axes to avoid anisotropy effects. Fortunately, this penalty is
usually not too severe when using single-shot DW-EPI techniques.
On MR systems incapable of performing measurements using
>2 b values, imaging could be performed using just the two higher
b values.
Recording of scanning parameters. To ensure maximum transpar-
ency, all pertinent scan parameters should be recorded and clearly
stated in reports, manuscripts, and other scientific publications. This
would facilitate investigators replicating the imaging technique on
similar platforms, translating techniques onto other imaging systems,
and enabling comparisons of ADC values between vendors.
Reporting of Imaging Parameters Should Ideally Include
the Following:
Field strength, MR system and model, gradient performance, soft-
ware version, field of view (FOV), matrix size, technique (e.g.,
breath-hold, free breathing, respiratory-triggered), type of imaging
sequence, TR, TE, number of partitions, section thickness, number
of averages (including the use of high b values averaging), fat sup-
pression technique, choice of b values, use of tetrahedral encoding,
receiver bandwidth, duration of application of diffusion gradient
(Δt), and time between application of diffusion-gradients (δt)
Accurate recording of imaging parameters may then be used to
retrospectively evaluate the relative value of techniques for optimizing
DW-MRI. Many of these parameters are already recorded in DICOM
header information and are retrievable. Obtaining access to this header
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information is critical for accurate image analysis. Magnetic resonance
imaging vendors should support access to this information in a move
toward greater transparency/standardization.
Diffusion-Weighted MRI Measurements
 Diffusion-weighted MRI should be optimized to maximize
SNR and to reduce artifacts that arise from motion, eddy cur-
rents, ghosting, and susceptibility effects.
 For visual qualitative analysis, DW-MRI should be performed
using b values, which result in sufficient background sup-
pression to allow signal intensity differences in target tissues
to be observed.
 For ADC quantification of a target tissue or lesion, two b val-
ues should be used (with one b value ≥ 100 sec/mm2 and
the other ≥500 but ≤1000 sec/mm2) with a monoexponen-
tial decay.
 There should be transparency in accessing and recording scan
parameters on all MR platforms in a move toward greater
standardization.
Analysis of DW-MRI Data
Analysis methods. For many clinical applications, single b-value
DW-MRI at relatively high diffusion weighting offers exceptional
sensitivity to detect disease (this is evident from experiences in the
brain for the early detection of stroke (on high–b value images) and
in the liver for the detection of lesions using “black blood” low–b value
images). However, image signal analysis from single b-value images is
inadequate for even rudimentary quantitative analysis of water mobil-
ity in tissue.
Multiple b values are necessary to calculate the ADC. At least two
b values are needed for basic ADC calculations and this can be done
on most clinical systems. Implicit in two b-value ADC calculations is
the application of a monoexponential decay model. That is, an ADC
map is generated by the natural logarithm of the ratio of low–b value
over high–b value image, scaled by inverse of the b-value difference.
Albeit overly simple, this two-point method is adequate in instances
where multiexponential features are negligible over the acquired b-
value range. Moreover, the adoption of this basic analysis has led to
reasonable agreement across centers and MRI vendors for ADC quan-
tification of the human brain (b-value range 0-1000 sec/mm2). Many
observers believe this may be sufficient for clinical usage, although it is
likely that physical measurement of water diffusion in tissue is more
complex than described by the monoexponential decay model.
In highly vascular tissue, blood flow/perfusion may impart signifi-
cant signal attenuation over the low b-value range (from b = 0 to b =
100 sec/mm2), which artificially inflates diffusion estimates. As de-
scribed above, nonzero lower b values should be used to eliminate
vascular contributions to the calculated ADC. The minimum b value
threshold to suppress perfusion effects will depend on the vascular
properties of tissues, although for most applications, a lower b value
of 100 to 150 sec/mm2 is probably adequate.
It is recommended to also continue to acquire the nominal “b = 0”
image to provide anatomic information and to maintain consistency
with prior work. Usually, the b = 0 image can be obtained at nearly
no cost in scan times using single-shot techniques, particularly be-
cause acquisition along three-orthogonal axes is not performed for
the b = 0 weighting.
For applications where DW-MRI is acquired over larger ranges
of diffusion sensitivities, and assuming perfusion effects have been
effectively removed by the proper choice of the lower b value, sim-
ple monoexponential models may not adequately characterize the
decay curve. Usually, evidence of true multiexponential features
(not related to perfusion effects) requires substantially higher b values
(e.g., 2000-6000 sec/mm2), much greater than is typically acquired
in clinical studies owing to practical SNR limits. Proper analysis of
these data types requires multiexponential models where signal de-
cays are modeled as weighted sums of two or more exponentials
(provided that the signals at the highest b value are above the noise
level) [10,11] or alternative models such as stretched exponentials
that allow a distribution of diffusion coefficients in each voxel
[12]. As with other curve fitting challenges, reliability to accurately
isolate multiple decay coefficients depends on the difference between
the true Dfast and Dslow, SNR, b-value range, and number of
b values acquired. Rejection of low SNR pixels and/or incorporation
of SNR weights in the multiexponential fitting routine should be
used to mitigate fitting errors. An unfortunate tradeoff in acquisi-
tion of DW-MRI over many b values and/or averaging to increase
SNR to support multiexponential diffusion analysis is the commen-
surate increases in scan times which may not be practical in many clini-
cal settings.
Diffusion in some tissues is known to be directionally dependent,
that is, anisotropic (e.g., in the central nervous system and in mus-
cle). If it is known a priori that the tissue of interest is isotropic (e.g.,
most tumor models) then a single gradient direction is usually suffi-
cient to properly document diffusion properties. In general, however,
it is safer to assume the lesion of interest and its surrounding tissues
may have directional dependencies so it is best to measure water
mobility along at least three orthogonal diffusion gradient directions
yielding, say, ADCx, ADCy, and ADCz. The simple average of these
into a mean diffusivity value effectively removes confounding influ-
ences of the relative orientation between tissue and the imaging
system. This mean diffusivity bears the same desirable rotational in-
dependence as the trace of the full diffusion tensor without having to
acquire or process DTI [70].
If further information is specifically desired regarding the strength
and spatial patterns of anisotropy, at least six gradient directions are
required to generate the full diffusion tensor, although additional gra-
dient directions (9-32 commonly) generally improve the quality of the
tensor analysis results.
Most MRI vendors offer the option to acquire and process DTI
scans in a reasonably efficient manner. Intrascan image registration
should be applied if there are systematic shifts and image distortions
at various gradient directions before tensor analysis. Multiple in-
dices are available to quantify the degree of anisotropy (e.g., FA,
relative anisotropy [70]). In addition, the direction of the strength
of anisotropy can be color-encoded using the principal eigenvector
of the diffusion tensor. Furthermore, the connectivity of anisotropic
domains can be represented in tractography, which allows visu-
alization of tissue fiber tracts in three dimensions [56]. As sug-
gested above, diffusion anisotropy is relatively strong in the CNS.
Outside the CNS with the exception of the kidney and muscle,
however, anisotropy is rather modest, and therefore, most tumor
analyses have been directed toward isotropic diffusivity indices (i.e.,
ADC calculations).
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Regions of interest definitions. To study diffusion properties of
tumor, proper delineation of lesion boundaries must be identified
for subsequent quantification. Ideally, the region of interest (ROI)
is contoured around lesions using images with the highest contrast
between lesion and normal tissue. Subjective placement of smaller
ROIs within lesions is not recommended particularly for response
assessment studies.
Traditional high-contrast anatomic images, such as T2-weighted
and contrast medium–enhanced T1-weighted, which are indepen-
dent of the DW-MRI sequences are preferred, but translation of
ROIs to the DW-MR image set is then required. Transferal of such
ROIs to the DW-MRI data set requires image registration unless pre-
scription of the traditional and DW-MRI scans was identical (ignor-
ing for the moment other systematic distortions). In some instances,
the DW images themselves can offer strong lesion/tissue contrast, in
which case these are sufficient for ROI definition. Ideally, the b0
T2-weighted image (or a very low b value image) should be used,
although, occasionally, higher b-value images may have to be used.
There is debate as to which b-value image best delineates tumor
from normal tissue/necrotic tissues. When ROIs are drawn on high–
b value images for the estimation of ADC values, such ROIs are said
to represent “viable tumor” because the detrimental effects of necrosis
are ameliorated. However, such a method for defining ROIs is occasion-
ally prone to error because of T2-shine through effects. Furthermore,
in the presence of necrosis/cystic structures, lesion extent maybe under-
estimated. It is also important to remember that well-differentiated tu-
mors may not be seen on high-value images. Whatever the method used
to define ROIs, a standard, recorded strategy should be applied to en-
sure consistency within any given study.
In the ADC calculation methods described above, low SNR pixel
values should be eliminated before the ADC map calculation, and
these pixels should be flagged as “not-a-number” for exclusion. How-
ever, elimination of low SNR pixels for ADC calculations and/
or using high–b value images for ROI definitions can be prob-
lematic when evaluating therapeutics effects of some drugs. For
example, chemotherapy for teratoma can cause a poorly differen-
tiated tumor to become well differentiated (a favorable outcome
measure) and some drugs/therapies induce necrosis and cystic de-
generation. In both cases, ROIs placed solely on areas of “viable
tumor, however, defined” would underestimate/mask favorable thera-
peutic effects. Pixel counting of zero ADC values before and after
being induced by therapy would be a way of dealing effectively with
these issues.
Conservative ROI definitions would only include apparently viable
tumor based on robust Gd contrast enhancement on T1-weighted im-
ages. A more generous tumor extent would include contrast-enhanced
and hyperintense tissues on T2-weighted images. However, inclusion of
necrotic and cystic zones can include extremes in water ADC values,
which may adversely bias image analysis. It is important that standard-
ized software be developed in which criteria of undesirable tissue be
clearly defined and that individual subjective decision making by ob-
servers is kept to a minimum. Different scenarios may be adopted to
exclude these nonviable tissue regions. It should be kept in mind that
a particular treatment might induce more nonviable voxels, which,
if eliminated from analysis, would falsely reduce the apparent impact
on ADC.
The entire three-dimensional volume of interest (VOI), a compos-
ite of ROIs over multiple slices, of the lesion should be delineated
particularly if the tumor is being followed over time.
Heterogeneity assessments. Volume of interest analyses methods
fall into three general areas: whole-tumor summary statistics, histo-
gram, and voxel-wise analyses.
(1) Whole-tumor summary statistics (e.g., mean and median) are
a common method for reduction of the tumor into a single quan-
tity. The advantage of this technique is its simplicity, although it
fails to fully address the important issue of tumor heterogeneity.
(2) The histogram-based approach subclassifies different tumor dif-
fusion environments [32]. For example, the volume of the tumor
within a specified range of the diffusion histogram has been inves-
tigated as an approach to document tumor evolution in response to
treatment. It is vital that consistent “binning” procedures be used
to analyze data across a multi-institutional trial because errors in
histogram comparisons have occurred where this was not standard-
ized [71]. When using histograms, redistributions of high and low
values may occur, and this may not be reflected in mean changes.
This occurs because histograms cannot depict the spatial informa-
tion as to the origin of changes, which may be crucial to detect the
evolution of diffusion changeswithin lesions. Ideally, advanced his-
togram analysis techniques should be used so that a single scalar
value can be used for developing response criteria on DW-MRI;
an example approach is principal component analysis [71].
(3) Ideally, to track the spatial origin of changes inducedby treatments,
it is necessary to have spatial tags to accurately monitor the change in
diffusivity [55,72]. The retention of spatial information requires
voxel-wise approaches incorporating registration of image data sets,
typically between treatment interval examinations. This method
seems to work well in the brain and in bones but is less likely to
be applicable to whole-body measurements owing to problems as-
sociated with image registration and changes in lesion sizes with
therapy [55,73]. This approach enables ADC in individual tumor
voxels to be followed and so enables the depiction of the fractions
exhibiting a significant change (increase or decrease) in ADC. The
spatial location of ADC changes within the tumor can be made
available to potentially guide spatially directed therapies.
Summary
Choice of monoexponential versus multiexponential modeling
of signal decay with b value depends on features apparent in
the data, SNR, number, and range of acquired b values.
Data typically obtained in most clinical applications for b-value
ranges of 100 to 1000 sec/mm2 are reasonably well modeled
using monoexponential decay fits.
Tumor ROI/VOI definitions may be done on traditional high-
contrast images such as T2-weighted or T1-weighted contrast-
enhanced images. High–image contrast, high–b value DW
images can also be used.
Descriptions of diffusion properties within lesions or tissues of
interest may be reported at several levels classified as follows:
1) traditional summary statistic over the entire ROI/VOI; 2)
histogram analysis, which allows segmentation of the tissue
based on diffusion properties; and 3) voxel-by-voxel analyses
where spatial information is retained over interval examinations
such that fractional volume of tissue exhibiting change in dif-
fusion properties is measurable. However, the latter requires
methods of tracking individual voxels over time.
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Correlations with End Points
The determination of outcome measures or end points must be
dictated by the nature of the question being address (clinical, biologic,
physical, or pharmaceutical). For instance, if the purpose of a trial
is to determine whether DW-MRI can characterize the biologic
aggressiveness of a tumor, then ADC values need to be correlated
with recognized measurements of aggressiveness. This could include
tumor grade, time to progression, progression-free survival, or over-
all survival. However, if the goal is to determine whether DW-MRI is
an early marker of treatment success, then intermediate end points
such as pathologic response could be used. Potentially, DW-MRI
results could be compared with other biomarker changes such as
serum markers of cancer (e.g., carcino embryonic antigen, prostate-
specific antigen, etc.), RECIST, and WHO measurements of tumor
size. However, firmer and more robust end points reflecting therapy
efficacy in patient outcomes are preferred where possible, such as time
to progression, progression-free survival, and overall survival.
If DW-MRI is being evaluated as an early biomarker of therapy
response then the timing of follow-up studies should be such that
DW-MRI is acquired before changes in size are expected to occur.
Intermediate time points may become influenced by necrosis and
liquefaction, and DW-MRI may become less useful. Long-term data
points may “normalize” because liquefactive necrosis resolves and the
residual mass contains fibrotic dehydrated tissues.
For response assessment studies, it is important to have prede-
termined whether DW-MRI changes are expected to occur, the
magnitude/direction of the likely change, and the timeline as to
when and for how long changes are expected to last. Animal valida-
tion studies before human studies may provide information on the
appropriateness of using DW-MRI and on the optimal timing for
doing imaging in human studies.
Data Display
Diffusion experiments generate large numbers of magnitude
b-value images. When these are combined with morphologic images,
many hundreds of images are produced, which need to be reduced
for diagnostic interpretations.
The most valuable images required for interpretation are high–
b value images and ADC maps, which should always be evaluated
with morphologic imaging. Because high–b value DW-MR images
have high background suppression, tumor localization is usually
straightforward. However, very high signal on high b value may also
be due to T2-shine through effects; conversely, liquefaction or necro-
sis can result in an underestimation of lesion extent, so comparisons
with anatomic images are important.
Although no color scales are especially suited for the display of
high–b value magnitude images, convention has it that “inverted gray-
scale” be used (ADC maps however, are better displayed using conven-
tional grayscale). Indeed, whole-body DW imaging with background
suppression can produce images that superficially resemble FDG-PET
scans (Figure 5). This is because of the high contrast on high–b value im-
ages, which, when used with three-dimensional displays, are amenable to
multiplanar reconstructions and three-dimensional renderings (maximum-
intensity projections, surface shaded display, volume renderings).
A common method of analyzing high–b value images is to use fusion
imaging techniques. Modern three-dimensional fusion imaging visuali-
zation software works in three steps. (1) Superimposition: data sets do
not need to be acquired in the same plane and to have identical FOVs
and matrix sizes, but most ADC data sets are aligned and obtained with
similar parameters. (2) Alignment: algorithms work with multiple de-
grees of freedom (translation and rotation) based on anatomic land-
marks with the ability to work automatically with manual overrides
if necessary. (3) Visualization: blending of grayscale with pseudo color
images with adjustable balance between the two superimposed data
sets. When blending is used for data display, the level of blending
should be kept constant across a study and reported in manuscripts.
Other potential artifacts appearing on fused images include mis-
registration of anatomic and DW images due to bladder filling and
internal organ including movements. Susceptibility artifacts caused
by luminal air are exaggerated on high–b value images, although their
effects are minimized on ADC maps.
Figure 5.Metastatic renal cancer. Whole-body DW image demonstrates (left to right). Coronal computed tomographic image, coronal T1-
weightedMRI at the sameplaneof section,DW imaging (b800) demonstrating left chestwallmetastasis and the fusedADCandT1-weightedMRI.
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Standardization
A major challenge to the widespread implementation of DW-MRI
is the lack of a standard approach to data collection and analysis. This
creates challenges for support of DW-MRI by commercial MRI ven-
dors and makes deployment of DW-MRI techniques limited to sites
with significant experimental MRI expertise. Furthermore, the lack
of standard approaches impairs validation and makes the ultimate
qualification of DW-MRI as a biomarker extremely difficult.
In large part, the lack of standardization is related to the technical
challenges in performing DW-MRI acquisitions. In most practical
applications of DW-MRI, performing “ideal” data acquisitions is im-
practical owing to limits in technology and patient compliance.
Approaches that accommodate technical limitations through com-
promises in acquisition and/or in analysis have been developed to allow
the practical implementation of this technique. Examples include re-
ducing the number of b values for modeling of data, reducing spatial
resolution, limiting volume of imaging, averaging free breathing stud-
ies instead of gating, using empiric analyses (e.g., visual assessments
signal intensity of high–b value images), creative acquisition time re-
ducing techniques, and so on.
Standardized data sets should be acquired systematically using
“ideal techniques” with great intrinsic redundancy to test the effect
of various technical compromises on measuring the signal associated
with response. Such data should be made widely available for inves-
tigators to test their analytic software. These ideal data sets should
be limited to single organs/single treatments starting with the least
challenging. Ideally these should be documented, anonymous, and
be available on the Web.
Similarly, it would be desirable for research groups to make their
analysis methods available either by publication of open code or under
specific bilateral agreements. In the longer term, specific standardized
software for analysis would be advantageous, but this should not re-
strict the continual evolution of measurement and analysis approaches.
Standard methods of diffusion assessment should be established and
validated against phantoms appropriate to specific body locations, with
their measurement reproducibility being established.
Recommendations for standardization
Basic standards for measurements/analysis and reporting of
tissue diffusion coefficient should be established and adhered
to. They should be tested against relevant phantoms, and re-
producibility should be established.
New techniques need to demonstrate specific advantages over
existing methods, providing comparison data that defines the
benefit.
Studies should include routine measurement and QA analysis.
Standardized data sets need to be made available to allow test-
ing and comparison of analysis approaches.
Research groups should make analysis methods available, either
as open source code or by specific agreements where there are
confidential or commercial issues.
Standardization of software for analysis would be desirable.
Validation
To support the use of DW-MRI parameters in decision making
about pharmaceuticals, it is important to link DW-MRI to underly-
ing pathophysiological processes both before and after interventions.
Initially, this should be performed in well-defined model systems
and then, where possible, confirmed by clinical measurements using
biopsy specimens or surrogate tissues. The link between DW-MRI
biomarker change and therapy response should also be established
in xenografts and then clinically using both clinical outcome mea-
sures as well as pathologic surrogates of outcomes. Ideally, these bio-
logic end points should relate specifically to the mechanism of action
of the compound.
Suggested histologic validation of DW-MRI includes exploring
links with measurements of proliferation index (Ki 67), cellularity
index (cells/high-power field), tumor grade, and apoptosis. It will also
be useful to explore/correlate DW-MRI with other MR measures of
perfusion (dynamic contrast-enhanced (DCE) MRI, dynamic sus-
ceptibility contrast MRI, blood oxygenation level–dependent MRI),
arterial spin labeling or metabolism magnetic resonance spectroscopy,
and other imaging tests (e.g., FDG-PET, thymidine-PET, or annexin
imaging for apoptosis).
Initially, clinical studies should validate practical approaches devel-
oped using the standardization guidelines described above, in more
generalized applications such as chemotherapy response at varieties of
anatomic sites. Neoadjuvant clinical trials are particularly suitable for
these purposes because pathologic materials obtained can serve as
rapid intermediate readouts/end points. If these are successful then
novel therapeutics in early phase 1/2 studies can be evaluated.
Validation of DW-MRI in Relation to End Points
Requires correlation between size and type of biologic effect
and relevant DW-MRI parameter, in animal models, sup-
ported by clinical biopsy or histology data.
Time course of effects will define the timing of imaging in
clinical trials.
Attempt to derive hypothesis-driven relationships between im-
aging and specific biologic end points.
Biologic end points should relate to the purported mechanism
of activity of the compound.
It would be desirable to be able to predict the magnitude of
the MR effect based on animal models, allowing trial design to
monitor dose-related change.
Reproducibility (See Also Appendix 3 for Detailed Methods)
To allow appropriate study design and to assess the significance of
change, centers should demonstrate the reproducibility of their clini-
cal measurements, in a manner that is traceable, providing informa-
tion on individual and intergroup reproducibility. This information
should be combined with evidence of the expected magnitude of
therapeutic effect, such that studies can enable assessments of dose-
related changes.
Reproducibility assessments are facilitated by incorporating baseline
repeated measurements to provide information directly relevant to the
body sites chosen. It is important to identify major sources of error
leading to nonreproducible results. To determine whether changes
in tumors induced by treatments are significant, three factors should
be known. These are the natural biologic variability of parameters
such as ADC, the variability inherent in the measuring instruments,
and knowledge of additional errors induced by appraisers or analy-
sis techniques. This implies that diffusion parameter measurement
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changes cannot be taken at face value without due consideration of
measurement errors. Estimates of measurement errors enable us to
decide whether changes in ADCs are “real” for both group and indi-
vidual observations.
Few published studies have documented measurement error in
body DW-MRI, and the major contributors toward errors are not
documented. However, from previous studies of other functional
imaging techniques (e.g., DCE MRI), it is likely that DW-MRI mea-
surement error will be dependent on a number of factors. These
include imaging instrumentation and setup procedures, data acquisition
techniques, and the time interval between repeated measurements.
Data analysis techniques are also likely to add to measurement error
including modeling techniques used (including range and noise of
b value images used and implicit assumptions (monoexponential vs bi-
exponential or multiexponential fitting)). Patient-related factors include
tumor type, anatomic region being evaluated, and underlying physio-
logic status of patients.
It is important that clinical trials evaluating DW-MRI responses to
treatment assess measurement variability as an intrinsic part of clinical
trial design. The measurement error estimate component should be of
sufficient statistical power (i.e., on enough patients) and needs to be
performed on the study patients or in other patients who are represen-
tative of those being examined in the main study. To compare mea-
surement errors of DW-MRI parameters at diverse anatomic sites and
pathologies, it is important that similar statistical methods be used and
that the meaning and limitations of statistical measures are understood.
Before statistical tests are applied, assumptions intrinsic to repro-
ducibility analysis must be verified (e.g., normality of data and the
nature of any relationship between measurement error and the mag-
nitude of the parameters). Appropriate statistical parameters include
the within-subject SD and coefficient of variance, and intraclass cor-
relation coefficient should be quoted in communications (as detailed
in Appendix 3). The repeatability statistic is a useful parameter for
DCE-MRI studies because it informs on whether changes in a par-
ticular patient are significant.
Reproducibility
Centers should define reproducibility of data that is traceable,
for individuals and intergroup comparisons, allowing the power
of studies to be defined prospectively for a defined end point.
Where possible, and in the absence of existing reproducibil-
ity data specific to the method, two baseline measurements
should be incorporated to allow assessment of individual pa-
tient reproducibility.
Multiple lesions per organ should be taken into account.
A standardized minimum statistical approach for reproducibil-
ity analysis should be reported.
Multicenter Methodology
In multicenter trials using identical (preferred) or similar methods
(such as maintaining a constant field strength, imaging a single organ,
etc.), comparison of precision and accuracy should be determined on
phantoms to provide a basis for pooling of data, with account taken of
corrections for machine-specific factors, and for sensitivity to motion
effects not seen in phantoms.
Site qualification should be undertaken by the performance of mea-
surements validated at a central analysis site before recruitment using
standardized data from each site. Readers should refer to Appendix 4
on QA procedures and diffusion phantoms for further details.
Analyses of DW-MRI data in multicenter trials should be per-
formed at a single center using a standardized validated software.
The reliability of analyses should be assured using data from each
participating center before starting the trial.
In each study, patient and lesion selection, as well as the number of
studies per patient including reproducibility assessments, should be
defined prospectively. Reproducibility studies should be done at each
imaging site because it provides estimates of measurement error in
multicenter settings but also serves as a quantitative QA measurement
of site performance. Standardized QA procedures should be enforced
on all institutions participating to keep the data as uniform as possible.
Every effort should be made to ensure that the study can proceed
on a given MR unit even if the unit is upgraded to a higher software
level. It is important for the viability of DW-MRI, as a biomarker that
implemented DW-MRI methods, be impervious to upgrades and soft-
ware changes; otherwise, its future as a biomarker is in question.
Robust data acquisition protocols that are able to deal effectively
with physiological motions should be instituted and adhered to.
Central data collections should incorporate appropriate QA and qual-
ity control procedures. Fast feedback to imaging sites is recommended to
minimize data loss due to incomplete or incorrect imaging. The number
and causes of failed examinations/analyses should be prospectively re-
corded. Ideally, failed examination/analysis rates should be <5% to 10%.
Data analysis should use a software that is fit for the purpose, is
validated, and is preferably Food and Drug Administration 21 CFR
part 11–compliant. 21 CFR Part 11 sets forth the requirements that
need to be met to have the Food and Drug Administration consider
electronic signatures and records equally trustworthy and just as
reliable as handwritten signatures. Validation of software algorithms
via multicenter trials is an essential need for obtaining regulatory ap-
proval to use DW-MRI as an accepted surrogate biomarker.
To promote the comparisons of ADC values obtained from different
centers and for differing therapies and to overcome the dependence
of ADC on the range of b values chosen for any particular study,
perfusion-insensitive ADC values (by excluding the b = 0 sec/mm2 im-
age from the ADC calculation) should always be quoted.
Additionally, study data should be publicly available to enable
alternative analytic approaches that might be superior to the ones
used in the study.
Multicenter Studies
Animal validation should be undertaken before human studies
to provide information on the appropriateness of using DW-
MRI and may be able to indicate the optimal timing for doing
imaging in human studies.
Double-baseline studies should be done to provide data about
measurement error of imaging specific to the study and thus
knowledge of what constitutes a significant change in an indi-
vidual and in a group of patients (powering studies).
Quantified parameters such as ADC should be measured to de-
rive physiologically meaning that can be related to drug mecha-
nisms of action. Quantified parameters have the advantage of
allowing interpatient and intrapatient comparisons to be made.
Good quality control and QA are keys to success for multicen-
ter studies.
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Software
Software applications that provide the means to standardize analysis
and display of DW-MRI data will facilitate the advancement of this
approach for diagnostic and therapeutic assessments in cancer imaging.
Software applications should allow efficient and reproducible analy-
ses of DW-MRI data using tools that allow zoom and pan function-
ality for two-dimensional and three-dimensional displays. Efficient
ROI/VOI delineations using anatomic and b-value images should
be available.
It is preferred that software incorporates intraexamination and in-
terexamination image registration. Image intensity–based spatial reg-
istration using mutual information is vital because it will allow for
voxel-wise changes to be followed over time in individuals.
The software should have a flexible workflow and should be able
to generate a variety of quantitative calculations for comparing tumor
diffusion values at multiple time points and to visualize therapy re-
sponse in individual, configurable layouts (Figure 6).
Overall, the standardized software will provide users with the abil-
ity to generate automatically a variety of quantitative calculations
based on volumetric analysis (histograms) or voxel-based analysis
over multiple time points and to visualize therapy response (an exam-
ple of voxel-based display is functional diffusion maps — fDM —
see Appendix 1).
Open source code should be used whenever possible to permit
broad dissemination of the method, thus encouraging standardi-
zation. The application should allow to import/export DICOM
data sets and to output measurements via schema-based XML to
data repositories.
Software
Diffusion-weighted MRI data require unique analysis approaches
for quantification of results.
Standardization of software applications for analysis of DW-MRI
data should provide for volumetric/histogram and for voxel-wise
quantification approaches.
Standardized software will provide for robust, standardized ap-
proaches for analysis of single and multisite clinical trials data
that can be used for regulatory submission.
Recommendations for Future
Methodology Development
Measurements
Development and testing of new acquisition protocols sensitized
to multiple directions with the objective of improving image quality
and reducing distortions and artifacts.
Improved robustness in whole-body DW-MRI techniques with in-
creased coverage and improved fat suppression.
Improved robustness of acquisition techniques able to deal with
physiological motions as dictated by specific anatomic locations are
Figure 6. Diffusion-weighted MRI used in treatment response monitoring. Top row demonstrates a perirectal mass (arrow) on T2-
weighted MRI, ADC, and the b750 gradient image in this patient with rectal cancer metastastic to a local lymph node. On chemotherapy,
the lesion has decreased in size but also has higher ADC values and corresponding lower signal on the b750 image. The changes in ADC
may be useful for monitoring response to therapy.
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needed to minimize smearing of data image, to reduce partial volume
averaging effects, and to preserve heterogeneity of ADC maps. The
relative benefits of motion-compensated and -independent measure-
ment techniques need systematic evaluation.
There is debate on the best phantom materials, options are de-
scribed in Appendix 4. Whatever material is ultimately used, there
is a pressing need for equipment manufacturers to specify clearly
QA procedures that they already do for SNR measurements.
Improved phantoms mimicking the cellular environment of living
tissue are required. Simple phantoms filled with liquids with different
diffusion coefficients measure diffusion coefficients and ADC. Phan-
toms filled with beads of well-controlled size may help us in under-
standing the properties of diffusion of extracellular water (provided
that susceptibility effects are negligible) but does not tell us anything
about other water diffusion components (vascular contributions and
intracellular). However, non-Gaussian distributions of the displace-
ment would be seen so these could be used initially.
It is recognized that improvements in SNR afforded by 3-T sys-
tems could be a boost for DW-MRI. It is accepted that diffusivity
is likely to be independent of field strength; however, the effect of
high field strengths on data acquisitions and analyses still needs to
be systematically evaluated.
Analysis Methods
Improvements in software for analyzing DW-MRI data are needed.
Such software should be adapted for “clinical” and “research” uses. Ide-
ally, the ability to generate synthetic b-value images back-calculated
from ADC/b values (less noise) would be valuable and could be
used to extrapolate very high b value images. The method of calculat-
ing ADC should be clear to the reader (via fitting displays, noise of
individual b-value images, and calculation error). There should be flex-
ible scaling of ADC images on displays and the ability to generate
ADC values for any given range of b values to promote the calculation
and reporting of perfusion-insensitive ADC values in clinical studies.
Low SNR pixel values should be eliminated before ADC map calcu-
lation, and these pixels should be flagged as “not-a-number” for exclu-
sion from subsequent analysis. The ability to segment (threshold)
high–b value/ADC images and then to obtain ADC values from
“threshold ROIs” using histograms are needed.
Fusion imaging techniques are invaluable for DW-MRI, and im-
proved registration in three-dimensional using mutual information
and warping techniques is needed.
Fusion methods need to be integrated into analysis and reporting/
communication tools. Fusion techniques need to be improved and ex-
tended with the ability to display, coregister, segment, fuse, and analyze
multiple functional imaging methods (DCE; blood oxygenation level–
dependent, magnetic resonance spectroscopic imaging, etc.) in an
integrated single work space. Such tools should allow for missing func-
tional data sets (not obtained, poor SNR, corruption, and artifacts).
It is becoming clear that DTI techniques provide information that
is valuable for investigating some organs such as the kidneys, muscle,
and the prostate gland. These efforts should be encouraged, and to
this end, robust data acquisition sequences and analysis software
should become more available.
Conclusions
Diffusion-weighted MRI is an attractive noninvasive, quantitative
technique that yields parameters that relate to tissue structure, cellu-
larity, and necrosis. The plethora of existing methods in the current
literature makes it impossible to conclude definitively that DW-MRI
is qualified as a pharmacodynamic marker of therapy response.
Therefore, the major outcome of this consensus document is to stim-
ulate funding agencies, vendors, and clinical trials to collaborate on
the design of multicenter studies that will test the value of DW-MRI
in more controlled circumstances than have hitherto been possible.
This will require focused groups of researchers to agree on precise
clinical scenarios in a variety of cancer types and on the timing of
imaging so as to address key biomarker development questions.
Agreements will be needed on data acquisition and analysis methods
that yield water diffusion biomarkers, on calibration tools, and statis-
tical methods for analyzing trial data. Although this task is complex,
the potential benefits are enormous given the ease with which DW-
MRI data can be incorporated into clinical trials. We hope that this
White Paper will catalyze action in this field so that these challenges
can be addressed in the near future.
Appendix 1. Nomenclature and Definitions
Anisotropy: A state in which a physical characteristic varies in value
along axes in different direction; a physical measurement made in one
direction differs from the measurement made in another direction.
Apparent diffusion coefficient (ADC) or diffusion map: A para-
metric image displaying coefficients derived from DW images. The
term apparent refers to the dependence of these coefficients on fac-
tors that alter the apparent mobility of free water.
b value: An attenuation factor related to the strength of applied
gradients on DW images; the higher the value b value, the stronger
the diffusion weighting (measured in seconds per square millimeter).
Increasing b value can be obtained by 1) increasing the strength
(height) of the diffusion gradient, 2) increasing its duration, and 3) in-
creasing the gap between the paired gradient lobes.
Diffusion-weighted MRI (DW-MRI): An MRI technique where
signal and contrast is determined by the microscopic mobility of
water. This mobility is due to thermal agitation and is influenced by
the cellular environment of the water. The term DW-MRI is preferred
to DWI, which commonly refers to “driving while intoxicated.”
Diffusion tensor imaging (DTI)/trace images: A sophisticated
form of diffusion imaging that allows the directionality and the mag-
nitude of water diffusion to be determined.
Diffusion coefficient: A constant of proportionality relating par-
ticle flux to the concentration gradient. The SI unit of is meters
squared per second. This is too large with respect to typical values
observed by MRI in tissues, and the unit millimeter squared per sec-
ond is recommended.
Functional diffusion map (fDM): a color overlay image of
therapeutic-induced ADC change within the tumor. The fDM pro-
vides the ability to objectively segment tumor into color regions
based on the magnitude and direction of ADC change.
Fractional anisotropy (FA): A DTI parameter that grades the
probability of water diffusion in the environment having a spherical
probability/being normalized. An FA value of 0 indicates a perfectly
spherical distribution of probability, whereas an FA value of 1 indi-
cates a completely definite direction of diffusion.
Intravoxel incoherent motion (IVIM): Flow-related dephasing of
magnetized water molecules within voxels resulting in signal losses on
low–b value images (<100 sec/mm2).
Isotropy: The quality of a property that does not depend on the
direction along which it is measured (has the same intensity regard-
less of the direction of measurement).
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Phase shifts: The process where protons lose coherence between
each other due to magnetic field inhomogeneities; diffusion gradients
have the sole purpose of enhancing the dephasing of spins thereby
accelerating signal losses that are only recovered for spins that have
remained static.
T2-shine through: A term denoting visibility or mildly hyperin-
tensity of tissues/structures related to the intrinsic T2-weighting of
DW images; usually stated to be present when mild hyper intensity
is seen on very high b value images (800-1000 sec/mm2) and on
ADC maps.
Appendix 2. Roadmap for DW-MRI Development as Response Biomarker
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Appendix 3. Measurement Error Methodology
The International Standards Organization (ISO: 5725) definitions
repeatability and reproducibility as follows:
1. Repeatability refers to test conditions that are as constant as pos-
sible, where the same operator using the same equipment within
a “short time interval” obtains independent test results with the
same method on identical items in the same laboratory.
2. Reproducibility refers to test conditions under which results are
obtained with the same method on identical test items but in
different laboratories with different operators using equipment.
Thus, repeatability refers to the ability of a measurement system to
provide consistent readings on a given object. A major requirement is
that external sources of error are controlled; in this case, only one
observer performs the measurement and the spontaneous variability
of the biologic parameter is assumed to change little during the brief
period. Repeatability thus informs on equipment variation. In MRI,
the repeated measurement of tissue relaxation properties without
moving the patient over a short period is thus a repeatability study.
It should be noted that repeatability is both a concept but also a spe-
cific statistical measure (see below).
Reproducibility, however, is the ability for multiple operators/
experiments to achieve consistent results on identical objects. Thus,
reproducibility measures the typical error between observers when
each observes the same quantity. Reproducibility informs on appraiser/
experimental variation. A DW-MRI measurement repeated on pa-
tients a few days apart is considered to be a reproducibility study. Even
if the equipment and analysis technique used for the two measure-
ments is identical, the experimental conditions are different because
of the timing element.
Appropriate statistical parameters include the within-subject SD
and coefficient of variance and interclass correlation coefficient.
The repeatability statistic is a useful parameter for DW-MRI studies
because it informs on whether changes in a particular patient are
significant. Before statistical tests are applied, assumptions intrinsic
to reproducibility analysis must be verified (normality of data and
the nature of any relationship between measurement error and the
magnitude of the parameters). Test-retest studies would need to
be performed within a short period (the same day would do pro-
vided that patients are taken off the imaging couch for a period
and a machine reboot takes place in a series of patients with the as-
sumption that no significant changes are expected to occur over such
a short period).
Measures of the spontaneous variability of parameter estimates
 Within subject coefficient of variation (wCV).
 Variance ratio (F ): ratio of the between-patient variance and
within-patient variance. A parameter with a larger variance in
the patient population, but a small variance within individual
patients (wCV) would have a higher variance ratio.
Measures of measurement error
 Intraclass correlation coefficient (ICC): a measure of the preci-
sion of parameter estimates (defining the reliability of the mea-
surement method).
 Repeatability statistic: threshold value (absolute value or per-
cent change) below which the absolute difference between
two measurements on the same patient (n = 1) is expected
to lie for 95% of pairs of observations.
Statistical calculations also need to take into account that there
may be more than one lesion measured per patient. Parameter val-
ues cannot be treated as independent samples because of the behav-
ior of tumors within a particular patient shares to a degree, a biologic
environment that is not common to other tumors. That is, some
correlation between tumors in a patient is expected, and this clus-
tering within patients needs to be taken into account in the methods
of statistical analyses. The latter is likely to affect not only measure-
ment error calculations but also the behavior of tumors owing to
the effect of treatment. About the latter, it is likely that the behav-
ior of tumors within a particular patient, due to treatment, is more
likely to have a higher correlation than the variation between differ-
ent patients.
Appendix 4. Diffusion Phantoms and
QA Procedures
Quality control procedures for DW-MRI can characterize the per-
formance of measurements obtained on clinical MRI systems and
can assist in clinical studies performed in centers where there maybe
limited specialist experience in diffusion imaging. Key features of
QA protocols are as follows: 1) preparation of test objects (phan-
toms), 2) the systematic application of DW-MRI procedures, and
3) the parameters chosen to analyze the results of QA protocols must
be helpful in identifying errors/deviations in the performance of
MRI systems. There is debate on the best phantom material (op-
tions are outlined below), but whatever material is used, there is a
pressing need for machine vendors to define clearly QA procedures
for DW-MRI.
Test Object Manufacture
Ideally, test objects should be made of material with tissue-equivalent
diffusions and MR signal properties (e.g., T2-relaxation rate). Mate-
rials should be inexpensive, easy to prepare in a reproducible way,
safe to transport, stable over time, and ideally nontoxic. However,
it is recognized that multiple, complex phantoms to validate ADC
measurements in multicenter clinical studies are difficult to make be-
cause the cellular environment of living tissues cannot be easily mim-
icked. Simple phantoms filled with gels/liquids with different
diffusion coefficients may be acceptable initially.
A number of liquids have been suggested as substances for diffu-
sion phantoms including the following:
1. Ice water is most dense, essentially 1.00 g/cm3, at 4°C. This
property makes ice water an attractive choice for a diffusion
phantom because the measurement will not be temperature sen-
sitive. Disadvantages include that fact that the free diffusion of
ice water is not similar to that found in biologic tissues. The T1-
relaxation rate of ice water is also long and requires measure-
ments with long TRs. However, the safety and availability of this
material are highly advantageous.
Water is a good choice of phantom for performing image quality
evaluations because the geometric effects are not normally ob-
served at the edge of phantoms, the problems associated with di-
electric standing wave effects do not affect the geometry of the
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sample, and the dielectric effects are independent of the effect of
motion-probing gradients (MPGs).
2. Alkanes hydrocarbons such as decane, dodecane, and tetracane
are thick, oily liquids of the paraffin series. These substances are
harmful and may cause lung damage if swallowed. They should
be used in original manufacturer’s delivery bottles. Dodecane
is nonhazardous for air, sea, and road freight and when used
in a sealed state and it has diffusion values close to that of brain
tissue [74].
3. Sucrose either used as an aqueous solution or used in combina-
tion with gels is a reliable test material whose properties can be
readily adjusted to obtain tissue-like relaxations and diffusion
properties [75,76]. Aqueous sucrose phantoms are easier to pro-
duce and are highly stable over time, although they require some
form of antibacterial treatment during manufacture.
4. Polydimethylsiloxane is a high-viscosity, high–molecular weight
polymer with a very low self-diffusion that is not detectable by
DW-MRI; it also has a very low relative permittivity value. It
is a useful material for evaluating a range of artifacts arising
from DW-MRI but is not a useful material for determining
ADC [77]. This is an excellent choice for phantom material be-
cause of the very low self-diffusion coefficient, resulting in no
image attenuation resulting from the application of MPGs, its
low dielectric constant eliminates standing wave problems; this
is an advantage at increased static field strengths. However, it is
also expensive.
4.1. When considering phantom development, the white matter
of normal brain has a highly reproducible ADC value (rang-
ing from 60 to 105 × 10−2 mm2/s [78,79] and might serve
as a “traveling living phantom.” Whereas the human brain
has been proposed as a standard for calibration because of
its stable temperature regulation, there are obvious limita-
tions to using a human “phantom” in the context of multi-
center trials.
Measurement Procedures
Whatever the final choice of diffusion phantom material used, the
following measurement conditions should apply.
 A scanner-specific QA measurement protocol should be pre-
pared in advance of the commencement of studies and should
not be changed for the duration of the study.
 Imaging coils should be identical to those used in proposed
clinical studies.
 Phantom position should be highly reproducible within the
coils used for the QA procedure. This can be achieved either
by the manufacture of positioning aids or with the use of bead-
filled vacuum bags (often used to assure positioning in radio-
therapy systems). Markers placed on phantoms can help to
ensure that alignment and positioning are reproduced.
 The shape of the phantom should be either spherical or cylindrical.
 The temperature of the phantom and the scanner room
should be recorded. Ideally, the phantoms should be left per-
manently in magnet rooms so that that temperature equilib-
rium is reached before scanning procedures are performed.
Phantom ADC measurements need to be adjusted to take into
account temperature because ADC increases by 2.5% per de-
gree Celsius [74]. The advantage of ice water as a test material
if used as an alternative is that it is always measured at the
same temperature and it eliminates temperature dependence
from measurements.
 Clearly, the FOV, b values, MPG directions, imagingmatrix, TR,
TE, parallel imaging factor, number of slices, slice positions, and
slice thickness must be held constant and be matched to clinical
protocols. Data should be acquired without filters or image cor-
rection algorithms.
 All QA procedures should be performed with and without the
use of fat suppression methods. The fat suppression method
may affect image quality, and the effect of fat suppression
method used should be evaluated.
 Because most clinical studies are performed with the acquisi-
tion of axial slices, the phantom setup should be designed to
evaluate the QA DW-MRI measurements in this orientation.
 For all clinical DW-MRI protocols using multiple MPG di-
rections, each MPG direction should be assessed indepen-
dently (e.g., ADCx, ADCy, ADCz) and ADC trace for the
range of b values used in the clinical protocol, this could be
restricted to two b values (b0 and largest b value used). Vari-
ability should be established for each directional measurement.
Apparent diffusion coefficient values should vary from less than
1% to 2% in each MPG direction for b values greater than b =
500 sec/mm2.
 Apparent diffusion coefficient calculations may be affected
by interactions of MPGs with the imaging gradients (a cross-
term phenomenon) particularly at lower b values and on re-
duced FOVs.
Quality Assurance Analyses
 Analyses should be on ADC measurements obtained using
methods described by Delakis et al. [75] about long-term fluc-
tuations of ADC measurements and directional variations of
ADC measurements.
 Diffusion decay curves should be evaluated to verify its monoex-
ponential nature (b values should be sufficiently large >200 sec/
mm2 to reduce the effect of imaging gradient cross-terms on
the actual b value). This is best achieved by performing a mul-
tiple averaged experiment, with TRs at least five times greater
than the sample T1 to produce very high SNR diffusion decay
curves. This should be evaluated in each direction that the
MPGs are applied. Three-scan trace (tetrahedral) approaches,
in general, do not enable users to evaluate the individual scan
measurement data because only trace images are produced (it
would be helpful if vendors provided an option to supply the
directional images).
 In general, machine vendors do not provide a suitable software
for evaluating the quality of the ADC fitting; this evaluation
will require the use of dedicated software tools to perform eval-
uations (several software tools are freely available on the Inter-
net). An ROI analysis can be performed using the vendor
software, and the mean value per b value from a central ROI
can be recorded and evaluated in a spreadsheet form using
commonly available software (e.g., Matlab, Microsoft Excel,
SPSS Inc. Sigmaplot, and many others). Significant data de-
viations from a monoexponential form or calculated ADC
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estimates at variance with the vendor software results should be
reported to vendors for remedial correction.
 Quality assurance measurements should be performed initially
on a daily/weekly basis to establish the variability in the mea-
surement data. Having established the variability for a given
scanner, QA procedures should be performed routinely on a
weekly basis and following any software/hardware changes.
 Records should be kept of QA analyses. Confidence limits
should be established from the initial QA measurement data,
and action procedures should be prescribed for QA measure-
ments results that fall outside the confidence intervals [80].
Quantifying Artifacts in DW-MRI
Methods of quantifying artifacts in a systematic way are helpful in
developing clinical protocols and maintaining image quality. Nondif-
fusing phantoms are well suited for this purpose. Apparent diffusion
coefficient maps generated from measurements on nondiffusing test
objects provide a direct indication of the source and magnitude of
artifacts. Nyquist ghosts and distortions can be quantified [80],
and protocols are optimized to reduce the magnitude of artifacts as
indicated in the next section [77].
Using Phantoms to Improve DW-MR Image Quality
All DW-MRI measurements are influenced by artifacts and ma-
chine imperfections. These include b0 inhomogeneity resulting from
susceptibility variations within biologic or physical test objects/samples
(this includes patients, volunteers, and nonhomogeneous structured
phantoms). Chemical shift artifacts result from the presence of more
than one chemical species or scalar coupling. Other artifacts are
measurement-induced, for example, Nyquist ghosting and geometric
distortions from residual MPG-induced eddy currents.
Before deciding on the measurement protocol for clinical studies,
artifacts should be characterized, and their effects minimized using
QA phantoms. There is extensive published literature on DTI inform-
ing on methods for improving DW-MR image quality [81,82]. Unfor-
tunately, most successful DTI correction techniques are not easily
applied in extracranial applications because of factors such as motion,
patient-induced b0 variations (including time variation), and chemical
shift artifacts from fat.
Phantom measurements can be used to improve the quality of
DW-MR images. One of the most challenging areas to tackle is
geometrical distortion (which occurs over large FOVs typically
used in extracranial imaging) resulting from residual eddy currents.
Large homogeneous phantoms (>20 cm) are suitable for the eval-
uation of in-plane geometric distortions and have the advantage
that they lack internal structures, which may confound the analy-
sis [83]. Measurements performed on these phantoms are easy to
evaluate using vendor measurement tools (distance and grid tools).
Subtraction images (the DW image is rescaled by the ratio of
mean values from the b0 and DW images and then subtracted from
the b0 image) enable the degree of geometric distortion to be visual-
ized easily.
Image distortion in clinical scanners can be improved in a number
of ways:
1. By reducing the amplitude of the higher b values either directly
or by using three-scan trace methods (these generally reduce the
amplitude of the individual gradients by a factor of 0.5-0.67 de-
pending on vendor implementation).
2. Increasing the pixel bandwidth (image bandwidth, increased fat-
water shift); this effectively reduces the length of the image read-
out and it may reduce image distortion and will reduce SNR. In
practice, the bandwidth is normally increased until Nyquist
ghosting becomes apparent in the images and is then subse-
quently reduced to an acceptable level.
3. Other choices include increasing the speed-up factor in the par-
allel imaging; factors greater than 2 can be problematic or un-
available depending on the scanner configuration.
4. Vendor-specific DW-MRI measurement methods exploiting the
use of double refocused spin echo with balanced MPG (zero
net MPG integral) are very effective in reducing eddy current–
induced distortions; they do incur a minor increase in the mini-
mum TE of the measurement [84].
Appendix 5. Sample 1.5-T Protocols
Brain Liver
Sequence type SS-EPI SS-EPI
FOV* (cm) 23 × 23 28-40
Matrix size* (x, y) 112 × 256 128 × 128; interpolate if possible
TR (msec) Shortest ≈ 4000 >2500
TE (msec) 89 Minimum
Fat suppression SPIR SPAIR/STIR
EPI factor 89 128
Parallel imaging factor N/A 2
Signal averages 1 4-7
Section thickness (mm)/gap 5/0 5-7/0-1
Directions of MPGs 3 directions 3 directions
b factors (mm2/sec) b = 0, 1000 Use three including b = 0, 50, or 100,
500, or 1000
Pixel bandwidth (Hz) 1833 1446
Patient preparation None Empty stomach
Other comments None Free breathing or respiratory-triggered
Imaging protocols are for 1.5-T systems.
*Rectangular to fit body size and shape.
SPIR indicates spectral presaturation with inversion recovery; WE, water excitation.
Pelvis Whole body*
Sequence type SS-EPI SS-EPI
FOV† (cm) 26 28-40
Matrix size† (x, y) 160 × 256 128 × 128; interpolate if possible
TR (msec) >3500 >2500
TE (msec) Minimum Minimum (<80)
Fat suppression STIR SPAIR/STIR
EPI factor 114 128
Parallel imaging 2 2
Signal averages 6 4-7
Section thickness (mm)/gap 6/1 5-7/0-1
Directions of MPGs 3 3
b factors (mm2/sec) 0, 100, 800 0, 50-100, 500-1000
Pixel bandwidth (Hz) 1000-1500 1000-1500
Patient preparation Antiperistaltic – i.m.
for longer action
Empty stomach
Other comments Free breathing Free breathing or respiratory-triggering
Imaging protocols are for 1.5-T systems.
*Koh DM, Takahara T, Imai Y, and Collins DJ (2007). Practical aspects of assessing tumors using
clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 6(4), 211–224.
†Rectangular to fit body size and shape.
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